 Humanigen Inc NASDAQ: HGEN has announced results from the Phase 1 trial evaluating its second Humaneered antibody, ifabotuzumab, in patients with glioblastoma multiforme GBM, the most frequent and lethal primary brain cancer. The results will be presented as a poster at the AACR Annual Meeting 2021. 